Table 2. Association between previous uterine myoma and subsequent occurrence of ovarian cancer, stratified by age group and use of hormone replacement therapy.
| Variables | Uterine myoma exposure | All patients (n=20,436) | Without ovarian cancer (n=16,348) | With ovarian cancer (n=4,088) | Crude OR (95% CI) | Adjusted OR (95% CI) | p-value | |
|---|---|---|---|---|---|---|---|---|
| All patients* | No | 17,942 (87.8) | 14,702 (89.9) | 3,240 (79.3) | Reference | Reference | ||
| Yes | 2,494 (12.2) | 1,646 (10.1) | 848 (20.7) | 2.34 (2.13–2.56) | 2.26 (2.06–2.49) | <0.001 | ||
| HRT use† | ||||||||
| No | No | 14,488 (90.0) | 11,887 (92.1) | 2,601 (81.6) | Reference | Reference | ||
| Yes | 1,609 (10.0) | 1,024 (7.9) | 585 (18.4) | 2.61 (2.34–2.91) | 2.51 (2.24–2.82) | <0.001 | ||
| Yes | No | 3,454 (79.6) | 2,815 (81.9) | 639 (70.8) | Reference | Reference | ||
| Yes | 885 (20.4) | 622 (18.1) | 263 (29.2) | 1.86 (1.57–2.20) | 1.79 (1.51–2.13) | <0.001 | ||
| Age group (yr)‡ | ||||||||
| 25–39 | No | 2,241 (93.0) | 1,846 (95.7) | 395 (82.0) | Reference | Reference | ||
| Yes | 169 (7.0) | 82 (4.3) | 87 (18.0) | 4.96 (3.60–6.83) | 4.25 (3.01–5.99) | <0.001 | ||
| 40–54 | No | 7,311 (81.7) | 6,051 (84.6) | 1,260 (70.4) | Reference | Reference | ||
| Yes | 1,635 (18.3) | 1,105 (15.4) | 530 (29.6) | 2.30 (2.04–2.60) | 2.16 (1.90–2.45) | <0.001 | ||
| 55–64 | No | 4,202 (87.7) | 3,422 (89.3) | 780 (81.4) | Reference | Reference | ||
| Yes | 588 (12.3) | 410 (10.7) | 178 (18.6) | 1.90 (1.57–2.31) | 1.91 (1.56–2.33) | <0.001 | ||
| ≥65 | No | 4,188 (97.6) | 3,383 (98.6) | 805 (93.8) | Reference | Reference | ||
| Yes | 102 (2.4) | 49 (1.4) | 53 (6.2) | 4.55 (3.06–6.75) | 4.29 (2.86–6.44) | <0.001 | ||
CI, confidence interval; HRT, hormone replacement therapy; OR, odds ratio.
*Adjusted for age, urbanization, monthly insurance premium, hypertension, diabetes, hyperlipidemia, endometriosis, HRT use, and number of medical visit; †Adjusted for age, urbanization, monthly insurance premium, hypertension, diabetes, hyperlipidemia, endometriosis, and number of medical visit; ‡Adjusted for urbanization, monthly insurance premium, hypertension, diabetes, hyperlipidemia, endometriosis, HRT use, and number of medical visit.